JOEL S MARCUS
CIK 1216955 · Executive Chairman · last filed 2026-05-07
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$55.04M
Companies
8
Total Filings
287
Lifetime Open-Market Net
-$156.07M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ARE | Executive Chairman | 587,724 | $48.12 | $28.28M | -$139.75M | 193 | 2026-05-07 |
| Intra-Cellular Therapies, Inc. (ITCI) Delisted | Director | 0 | $131.87 | $0 | -$13.07M | 43 | 2025-04-02 |
| Applied Therapeutics, Inc. (APLT) Delisted | Director | 565,849 | $0.10 | $58.3K | -$257.6K | 15 | 2024-06-07 |
| Korro Bio, Inc. (FREQ) Delisted | Director | 26,377 | $14.98 | $395.1K | -$1.32M | 11 | 2022-08-19 |
| MGTX | Director | 1,995,608 | $13.14 | $26.22M | -$294.2K | 7 | 2022-06-09 |
| ATRA | Director | 460 | $8.94 | $4.1K | -$1.52M | 12 | 2019-03-19 |
| REXR | Director | 12,858 | $36.19 | $465.3K | $140.0K | 1 | 2013-07-24 |
| PMT | Director | 7,000 | $9.45 | $66.2K | $0 | 2 | 2012-05-18 |
Recent Filings · Page 13 of 29
287 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-11-05 | ARE | Sell (S) | −10,000 | -$1.23M | EDGAR |
| 2018-08-22 | ARE | Sell (S) | −10,000 | -$1.28M | EDGAR |
| 2018-08-06 | ARE | Sell (S) | −29,500 | -$3.74M | EDGAR |
| 2018-06-20 | Intra-Cellular Therapies, Inc. (ITCI) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-06-18 | ATRA | Grant (A) | +1,500 | $0 | EDGAR |
| 2018-05-14 | ARE | Sell (S) | −13,000 | -$1.69M | EDGAR |
| 2018-05-09 | ARE | Sell (S) | −20,000 | -$2.57M | EDGAR |
| 2018-05-07 | ARE | Sell (S) | −25,000 | -$3.19M | EDGAR |
| 2018-04-02 | ARE | Grant (A) | +25,000 | $0 | EDGAR |
| 2018-02-20 | ARE | Sell (S) | −5,000 | -$604.3K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.